Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Xenon Pharmaceuticals, focused on neurology, announced its participation in key investor conferences. The Jefferies Biotech on the Bay Summit is scheduled for April 26-27, 2022, in Miami, FL, featuring one-on-one meetings. The Bloom Burton & Co. Healthcare Investor Conference will take place on May 2-3, 2022, in Toronto, with a presentation on May 3 at 11:30 am ET. Lastly, the RBC Capital Markets Global Healthcare Conference will occur on May 17-18, 2022, in New York, highlighted by a fireside chat on May 18 at 11:00 am ET. For further details, visit Xenon's investor page.
Positive
- None.
Negative
- None.
Insights
Analyzing...
BURNABY, British Columbia, April 25, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company today announced that Xenon’s management team will participate in the following investor conferences:
| Jefferies Biotech on the Bay Summit | |
| Date/Location: | April 26-27, 2022 in Miami, FL (one-on-one investor meetings only) |
| Bloom Burton & Co. Healthcare Investor Conference 2022 | |
| Date/Location: | May 2-3, 2022 at the Metro Toronto Convention Centre in Toronto, ON |
| Presentation: | Tuesday, May 3, 2022 |
| Time: | 11:30 am Eastern Time |
| 2022 RBC Capital Markets Global Healthcare Conference | |
| Date/Location: | May 17-18, 2022 at the InterContinental Barclay in New York, NY |
| Fireside Chat: | Wednesday, May 18, 2022 |
| Time: | 11:00 am Eastern Time |
Details on company presentations and webcasts can be found on the “Investors” section of Xenon’s website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com